Purpose of the Procedure
- Screening for Lynch syndrome, a hereditary condition increasing cancer risk.
- Determining if the tumor is likely to respond to immunotherapy drugs.
- Assessing the functionality of the DNA mismatch repair system in tumor cells.
Book MMR IHC Test in Saudi Arabia | Lahalak Medical Platform
MMR testing is essential for identifying Lynch syndrome and determining eligibility for immunotherapy in oncology patients, providing a personalized roadmap for more effective cancer treatment and management.
Scientific name: Mismatch Repair (MMR) Immunohistochemistry
An immunohistochemistry test measuring MLH1, MSH2, MSH6, and PMS2 protein expression in tumor tissue to screen for Lynch syndrome and guide immunotherapy selection.
Service type
Histopathology & Immunohistochemistry
Duration
3-5 working days
Fasting
Fasting is not required
Included Services
- MLH1 Protein Staining
- MSH2 Protein Staining
- MSH6 Protein Staining
- PMS2 Protein Staining
Medical Service Information
Who Should Get This Test?
- Patients diagnosed with colorectal cancer to guide treatment.
- Patients with endometrial (uterine) cancer.
- Individuals with a strong family history of Lynch syndrome-related cancers.
Understanding Results
- Intact Expression: Means the MMR proteins are functioning normally.
- Loss of Expression: Indicates a deficiency (dMMR), suggesting potential benefit from immunotherapy or need for genetic counseling.
Conditions & Notices
- Requires a tissue biopsy sample from the tumor
- Previous pathology reports must be provided
Medical services you might also like
